Previous close | 38.71 |
Open | 38.75 |
Bid | 38.90 x 100 |
Ask | 38.97 x 100 |
Day's range | 38.75 - 39.42 |
52-week range | 29.85 - 45.00 |
Volume | |
Avg. volume | 1,061,488 |
Market cap | 4.951B |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | 18.56 |
EPS (TTM) | 2.10 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 51.11 |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.